NO20062399L - Transdermale smertestillende systemer som har redusert misbrukspotensial - Google Patents

Transdermale smertestillende systemer som har redusert misbrukspotensial

Info

Publication number
NO20062399L
NO20062399L NO20062399A NO20062399A NO20062399L NO 20062399 L NO20062399 L NO 20062399L NO 20062399 A NO20062399 A NO 20062399A NO 20062399 A NO20062399 A NO 20062399A NO 20062399 L NO20062399 L NO 20062399L
Authority
NO
Norway
Prior art keywords
transdermal
painkillers
abuse potential
abuse
reduced abuse
Prior art date
Application number
NO20062399A
Other languages
English (en)
Inventor
Jay Audett
Thomas M Stein
Robert Gale
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20062399L publication Critical patent/NO20062399L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Et transdermalt smertestillende system som har redusert potensiale for misbruk, hvori systemet tilveiebringer den kontrollerte frigjøringen av antagonisten ved en hastighet tilstrekkelig til å tilveiebringe et misbruksbegrensende frigjøringshastighetsforhold av antagonisten til det smertestillende midlet hvor doseringsformen er utsatt for misbruk blir utgreiet.
NO20062399A 2003-10-30 2006-05-26 Transdermale smertestillende systemer som har redusert misbrukspotensial NO20062399L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51562503P 2003-10-30 2003-10-30
PCT/US2004/035988 WO2005044243A2 (en) 2003-10-30 2004-10-27 Transdermal analgesic systems having reduced abuse potential

Publications (1)

Publication Number Publication Date
NO20062399L true NO20062399L (no) 2006-07-19

Family

ID=34572844

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062399A NO20062399L (no) 2003-10-30 2006-05-26 Transdermale smertestillende systemer som har redusert misbrukspotensial

Country Status (11)

Country Link
US (1) US20050095279A1 (no)
EP (2) EP1677771A2 (no)
JP (1) JP2007527415A (no)
KR (1) KR20060120678A (no)
CN (1) CN1909892A (no)
AU (2) AU2004286852A1 (no)
CA (1) CA2543610A1 (no)
IL (1) IL175313A0 (no)
NO (1) NO20062399L (no)
WO (1) WO2005044243A2 (no)
ZA (1) ZA200604371B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
DE02715112T1 (de) * 2001-03-16 2007-04-19 Alza Corp., Mountain View Transdermales pflaster zur verabreichung von fentanyl
DE60336394D1 (de) * 2002-04-23 2011-04-28 Durect Corp Transdermale analgetische systeme mit reduziertem missbrauchspotential
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
ATE471146T1 (de) 2004-10-21 2010-07-15 Durect Corp Transdermale verabreichungssysteme
WO2007035942A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal risperidone delivery system
WO2007070632A2 (en) * 2005-12-13 2007-06-21 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US7740879B2 (en) * 2006-01-17 2010-06-22 Harrogate Holdings Abuse resistant transdermal drug delivery patch
US20070259029A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water-dispersible patch containing an active agent for dermal delivery
US20070258935A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water dispersible films for delivery of active agents to the epidermis
US20080008747A1 (en) * 2006-07-07 2008-01-10 Royds Robert B Transdermal patch
AU2007275581B2 (en) 2006-07-21 2011-09-08 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
US20080057090A1 (en) * 2006-09-01 2008-03-06 Mcentire Edward Enns Wrinkle masking film composition for skin
US7879942B2 (en) * 2006-10-05 2011-02-01 Eastman Chemical Company Switchable adhesive article for attachment to skin and method of using the same
US8399475B2 (en) * 2007-04-12 2013-03-19 Mallinckrodt Llc Crystalline and amorphous forms of naltrexone hydrochloride
NZ584190A (en) * 2007-10-15 2012-09-28 Alza Corp Once-a-day replacement transdermal administration of fentanyl
EP2254561A2 (en) * 2008-03-26 2010-12-01 AllTranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
AU2009271271A1 (en) * 2008-06-23 2010-01-21 Biodelivery Sciences International, Inc. Multidirectional mucosal delivery devices and methods of use
CA2795158C (en) * 2010-04-02 2019-10-22 Alltranz Inc. Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
KR20150036825A (ko) 2010-04-13 2015-04-07 나지브 바불 1-메틸-2''-6''-피페콜옥실리디드의 피부 약제학적 조성물 및 사용 방법
WO2013026064A1 (en) 2011-08-18 2013-02-21 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
CN103930098B (zh) * 2011-09-22 2017-06-06 株式会社三养生物制药 含有芬太尼及其同族体的经皮吸收制剂
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
PL3096746T3 (pl) * 2014-01-22 2019-09-30 4P Therapeutics Systemy transdermalne zapobiegające nadużywaniu i niewłaściwemu użyciu
WO2016049266A1 (en) * 2014-09-24 2016-03-31 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
WO2017053936A1 (en) 2015-09-24 2017-03-30 Pain Therapeutic, Inc. Cocrystals of naloxone and naltrexone
WO2020008366A1 (en) * 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal dosage form
WO2020008370A1 (en) * 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal patch
WO2020009685A1 (en) * 2018-07-02 2020-01-09 John Tang Transdermal dosage form
CN110013602B (zh) * 2019-04-17 2021-10-26 杨高云 用于治疗肢端型白癜风的手套及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493657A (en) * 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US5310559A (en) 1982-09-01 1994-05-10 Hercon Laboratories Corporation Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5006342A (en) 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US5186939A (en) * 1987-04-23 1993-02-16 Cygnus Therapeutic Systems Laminated composite for transdermal administration of fentanyl
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5762952A (en) 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
US6103258A (en) * 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
TW411277B (en) 1996-05-13 2000-11-11 Hisamitsu Pharmaceutical Co Percutaneous tape preparation containing fentanyl
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
AU4990797A (en) * 1996-10-24 1998-05-15 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
DE19653606A1 (de) 1996-12-20 1998-06-25 Roehm Gmbh Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher
DE19653605C2 (de) 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
AU776666B2 (en) 2000-02-08 2004-09-16 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
DE02715112T1 (de) 2001-03-16 2007-04-19 Alza Corp., Mountain View Transdermales pflaster zur verabreichung von fentanyl
EP2062573B1 (en) * 2001-05-01 2011-11-16 Euro-Celtique S.A. Abuse resistant opioid containing transdermal systems
DE60336394D1 (de) * 2002-04-23 2011-04-28 Durect Corp Transdermale analgetische systeme mit reduziertem missbrauchspotential

Also Published As

Publication number Publication date
WO2005044243A3 (en) 2006-03-30
ZA200604371B (en) 2007-09-26
CA2543610A1 (en) 2005-05-19
AU2010202357A1 (en) 2010-07-01
JP2007527415A (ja) 2007-09-27
EP2269606A3 (en) 2012-04-25
IL175313A0 (en) 2006-09-05
CN1909892A (zh) 2007-02-07
KR20060120678A (ko) 2006-11-27
WO2005044243A8 (en) 2005-09-09
EP2269606A2 (en) 2011-01-05
US20050095279A1 (en) 2005-05-05
EP1677771A2 (en) 2006-07-12
AU2004286852A1 (en) 2005-05-19
WO2005044243A2 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
WO2005044243A3 (en) Transdermal analgesic systems having reduced abuse potential
NO20045034L (no) Transdermale analgetiske systemer med redusert misbrukspotensiale
UA83257C2 (en) Allosteric modulators of metabotropic glutamate receptors
NO20054682L (no) Sikker transdermal doseringsform
MX2009008051A (es) Regimen posologico para inhibidores de comt.
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
MXPA05006737A (es) Forma de dosificacion solida para ingrediente activo labil en acido.
ATE479687T1 (de) Kinaseinhibitoren
MA32934B1 (fr) Combinaisons inhibitrices hsp90
DK2114383T3 (da) Små-volumen orale transmukosale doseringsformer indeholdende sufentanil til behandling af smerte
FI7750U1 (fi) Annostusmuoto, joka sisältää oksikodonia ja naloksonia
DK1729746T3 (da) Anordning til transdermal administration af nikotin
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
NO20073065L (no) Injiserbare nanopartikulaere olanzapinformuleringer
SG169353A1 (en) Tamper resistant dosage forms
NO20072199L (no) Trombopoietinaktivitetsmodulerende forbindelser og fremgangsmater
NO20070907L (no) Pyrrolo-pyridin kinase modulatorer
WO2005086836A3 (en) Ion channel modulators
UA92496C2 (ru) Производные оксадиазола и их применение как положительных аллостерических модуляторов метаботропных глутаматных рецепторов
EP2275115A3 (en) Inhibition of stress-induced ligand-dependent EGFR activation
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
WO2005086895A3 (en) Ion channel modulators
TW200603783A (en) Non-nucleoside reverse transcriptase inhibitors
NO20072832L (no) Smertestillende middel